Merck KGaA Partners with AI Techbio Caris Discovery for ADC Discovery, Up to $1.4 Billion in Milestones

1. Merck KGaA has entered into an ADC discovery agreement with AI techbio Caris Discovery, as reported on April 4, 2024.
2. The deal has the potential to reach up to $1.4 billion in milestones.
3. Caris Discovery will receive an undisclosed upfront payment and research funding, and is eligible for milestone payments based on the success of the collaboration.
4. The partnership aims to identify and develop new antibody-drug conjugates (ADCs) using Caris Discovery's ADAPT Biotargeting platform, patient tissue repository, and AI-based technologies.
5. Merck KGaA will assume responsibility for preclinical research through commercialization for ADCs against up to 15 selected targets, receiving global licenses for these ADCs.